Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)

v3.26.1
Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Information    
Number of reportable segments | segment 1  
Operating expenses:    
Total research and development $ 2,669,779 $ 2,436,998
General and administrative expenses 2,406,587 1,992,928
Total operating expenses 5,076,366 4,429,926
Sublease income (19,455)  
Loss on debt conversion with related party   6,134,120
Exchange loss, net 5,860 23,274
Net loss before income taxes 4,986,614 10,924,952
Single reportable segment    
Operating expenses:    
Clinical 1,809,420 1,817,232
Chemical, manufacturing and controls 265,725 135,122
Research and preclinical (5,634) 24,134
Regulatory 14,662 21,658
Other research and development costs 585,606 438,852
Total research and development 2,669,779 2,436,998
General and administrative expenses 2,406,587 1,992,928
Total operating expenses 5,076,366 4,429,926
Sublease income (19,455)  
Loss on debt conversion with related party   6,134,120
Interest (income)/expense, net (77,350) 147,090
Exchange loss, net 5,860 23,274
Net loss before income taxes $ 4,985,421 $ 10,734,410